Sees FY25 operational sales growth of 2.5%-3.5%, consensus $91.09B.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
- Johnson & Johnson’s Nasal Spray Gets FDA Nod for Depression Treatment
- Intra-Cellular downgraded to Sector Perform from Outperform at RBC Capital
- Notable companies reporting before tomorrow’s open
- Johnson & Johnson announces FDA approves sNDA for Spravato